poisar

Stocks · News reference

Wells Fargo Maintains Overweight on Merck & Co, Raises Price Target to $170

Benzinga Newsdesk
Read original sourceMore stocks news

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

MRK
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. David Dierking

    Want $500 a Month in Passive Income? Start With This Brilliant Dividend ETF.

    The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as an effective vehicle for generating sustainable passive income through dividends. With a 3.2% yield and a history of increasing annual dividends since 2011, investors would need approximately $187,500 invested to generate $500 monthly in dividend income. The fund focuses on high-quality dividend-paying stocks and has delivered 13.4% annual returns since inception.

    Read original at the-motley-fool
    SCHDMRKAMGNABBV
  2. Prosper Junior Bakiny

    BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?

    BioNTech and Moderna, both mRNA vaccine pioneers during the pandemic, are now pivoting to cancer vaccines as COVID revenue declines. Moderna is favored due to stronger recent clinical progress, including positive phase 3 results for its personalized cancer vaccine intismeran autogene and FDA approval for mFLUSIVA flu vaccine. While BioNTech has a deep pipeline including pumitamig, it has yet to deliver comparable phase 3 wins. Moderna's $61.2 billion market cap reflects investor confidence in its near-term commercialization prospects versus BioNTech's $26 billion valuation.

    Read original at the-motley-fool
    BNTXMRNAMRKBMYCELGR
  3. Na

    Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?

    Moderna secured FDA approval for mFlusiva, the first mRNA-based seasonal flu vaccine, establishing a foothold in the multibillion-dollar flu vaccine market. However, GSK announced plans to advance its own mRNA flu vaccine into phase III trials, which targets two viral proteins (HA and NA) and showed superior immune responses in phase II studies. While GSK's vaccine is still years away from market approval, it could pose a competitive challenge to Moderna's mFlusiva, which currently targets only HA like traditional flu vaccines.

    Read original at zacks-investment-research
    MRNAGSKMRKSNY